Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.060
+0.010 (0.49%)
Jan 21, 2025, 4:00 PM EST - Market closed
Neumora Therapeutics Employees
Neumora Therapeutics had 124 employees as of December 31, 2023. The number of employees increased by 30 or 31.91% compared to the previous year.
Employees
124
Change (1Y)
30
Growth (1Y)
31.91%
Revenue / Employee
n/a
Profits / Employee
-$2,368,532
Market Cap
332.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Dec 31, 2021 | 88 | 35 | 66.04% |
| Dec 31, 2020 | 53 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NMRA News
- 19 days ago - Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA - Business Wire
- 19 days ago - Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals - Investopedia
- 19 days ago - Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals - Market Watch
- 19 days ago - Neumora Therapeutics' depression drug fails to meet main goal of late-stage study - Reuters
- 19 days ago - Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder - GlobeNewsWire
- 4 weeks ago - Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck - Seeking Alpha
- 2 months ago - This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho - Market Watch
- 2 months ago - Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript - Seeking Alpha